The prognostic significance of cytogenetic aberrations in childhood acute myeloid leukaemia. A study of the Swiss Paediatric Oncology Group (SPOG)
David R. Betts
Department of Oncology, University Children’s Hospital, Zurich
Search for more papers by this authorRoland A. Ammann
Department of Hematology and Oncology, University Children’s Hospital, Bern
Search for more papers by this authorAndreas Hirt
Department of Hematology and Oncology, University Children’s Hospital, Bern
Search for more papers by this authorHeinz Hengartner
Department of Oncology and Hematology, Children’s Hospital, St Gallen
Search for more papers by this authorMaja Beck-Popovic
Pediatric Hematology-Oncology Unit, CHUV, Lausanne
Search for more papers by this authorThomas Kuhne
Department of Oncology and Hematology, University Children’s Hospital, Basel
Search for more papers by this authorLuisa Nobile
Department of Oncology, Children’s Hospital, Locarno
Search for more papers by this authorUeli Caflisch
Department of Oncology, Children’s Hospital, Luzern
Search for more papers by this authorPierre Wacker
Department of Oncology, University Children’s Hospital, Geneva, Switzerland
Search for more papers by this authorFelix K. Niggli
Department of Oncology, University Children’s Hospital, Zurich
Search for more papers by this authorDavid R. Betts
Department of Oncology, University Children’s Hospital, Zurich
Search for more papers by this authorRoland A. Ammann
Department of Hematology and Oncology, University Children’s Hospital, Bern
Search for more papers by this authorAndreas Hirt
Department of Hematology and Oncology, University Children’s Hospital, Bern
Search for more papers by this authorHeinz Hengartner
Department of Oncology and Hematology, Children’s Hospital, St Gallen
Search for more papers by this authorMaja Beck-Popovic
Pediatric Hematology-Oncology Unit, CHUV, Lausanne
Search for more papers by this authorThomas Kuhne
Department of Oncology and Hematology, University Children’s Hospital, Basel
Search for more papers by this authorLuisa Nobile
Department of Oncology, Children’s Hospital, Locarno
Search for more papers by this authorUeli Caflisch
Department of Oncology, Children’s Hospital, Luzern
Search for more papers by this authorPierre Wacker
Department of Oncology, University Children’s Hospital, Geneva, Switzerland
Search for more papers by this authorFelix K. Niggli
Department of Oncology, University Children’s Hospital, Zurich
Search for more papers by this authorAbstract
In childhood-onset acute myeloid leukaemia (AML) the clinical value of karyotypic aberrations is now acknowledged, although there is still debate concerning the prognostic significance of some events. To add to this knowledge, cytogenetic analysis was performed on a consecutive series of 84 childhood AML patients diagnosed in Switzerland. A result was obtained for all patients, with 69 (82%) showing a clonal karyotypic aberration. In the remaining 15 (18%), no karyotypic aberration was seen by either conventional or fluorescence in situ hybridisation analyses. The most frequent aberrations observed were t(11q23) (19% of all patients), t(8;21) (12%) and +8 (11%). Except for cytogenetics, no clinical parameter was shown to be significantly associated with outcome. The analysis of individual cytogenetic subgroups demonstrated that aberrations involving chromosome 16q were the strongest predictor of a good prognosis, while +8 and complex karyotypes represented the strongest predictors of a poor prognosis. It was also noteworthy that patients with the rare aberrations of del(11q) (n = 4) and t(16;21)(p11;q22) (n = 3) had a poor outcome. The results support the importance of cytogenetic analysis in childhood AML, but show that further work is required in the classification of the poor prognosis aberrations.
References
- 1 Creutzig U, Zimmermann M, Ritter J, et al. Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials. Leukemia 2005; 19: 2030–42.
- 2 Entz-Werle N, Suciu S, Van Der Werff ten Bosch J, et al. Results of 58872 and 58921 trials in acute myeloblastic leukemia and relative value of chemotherapy vs allogeneic bone marrow transplantation in first complete remission: the EORTC Children Leukemia Group report. Leukemia 2005; 19: 2072–81.
- 3 Gibson BES, Wheatley K, Hann IM, Stevens RF, Webb D, Hills RK, De Graaf SSN, Harrison CJ, for the United Kingdom Childhood Leukaemia Working Party, The Dutch Childhood Oncology Group. Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials. Leukemia 2005; 19: 2130–8.
- 4 Kardos G, Zwaan CM, Kaspers GJL, et al. Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials. Leukemia 2005; 19: 2063–71.
- 5 Lie SO, Abrahamsson J, Clausen N, et al. Long-term results in children with AML: NOPHO-AML Study Group – report of three consecutive trials. Leukemia 2005; 19: 2090–100.
- 6 Perel Y, Auvrignon A, Leblanc T, et al. Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit – multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group. Leukemia 2005; 19: 2082–9.
- 7 Pession A, Rondelli R, Basso G, Rizzari C, Testi AM, Fagioli F, De Stefano P, Locatelli F, and on behalf of the AML Strategy Study Committee of the Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP). Treatment and long-term results in children with acute myeloid leukaemia treated according to the AIEOP AML protocols. Leukemia 2005; 19: 2043–53.
- 8 Ravindranath Y, Chang M, Steuber CP, et al. Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000. Leukemia 2005; 19: 2101–16.
- 9 Ribeiro RC, Razzouk BI, Pounds S, Hijiya N, Pui C-H, Rubnitz JE. Successive clinical trials for childhood acute myeloid leukemia at St Jude Children’s Research Hospital, from 1980 to 2000. Leukemia 2005; 19: 2125–9.
- 10 Smith FO, Alonzo TA, Gerbing RB, Woods WG, Arceci RJ, for the Children’s Cancer Group. Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children’s Cancer Group: CCG 251, CCG 213 and CCG 2891. Leukemia 2005; 19: 2054–62.
- 11
Bloomfield CD,
Shuma C,
Regal L,
et al.
Long-term survival of patients with acute myeloid leukemia: a third follow-up of the Fourth International Workshop on Chromosomes in Leukemia.
Cancer
1997; 80: 2191–8.
10.1002/(SICI)1097-0142(19971201)80:11+<2191::AID-CNCR5>3.0.CO;2-L CAS PubMed Web of Science® Google Scholar
- 12 Grimwade D, Walker H, Oliver F, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 1998; 92: 2322–33.
- 13 Byrd JC, Mrózek K, Dodge RK, et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). Blood 2002; 100: 4325–36.
- 14 Martinez-Climent JA, Lane NJ, Rubin CM, et al. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia 1995; 9: 95–101.
- 15 Raimondi SC, Chang MN, Ravindranath Y, Behm FG, Gresik MV, Steuber CP, Weinstein JH, Carroll AJ, for the Pediatric Oncology Group. Chromosomal abnormalities in 478 children with acute myeloid leukemia: clinical characteristics and treatment outcome in a Cooperative Pediatric Oncology Group Study – POG 8821. Blood 1999; 94: 3707–16.
- 16 Forestier E, Heim S, Blennow E, et al. Cytogenetic abnormalities in childhood acute myeloid leukaemia: a Nordic series comprising all children enrolled in the NOPHO-93-AML trial between 1993 and 2001. Brit J Haematol 2003; 121: 566–77.
- 17 Stark B, Jeison M, Gabay LG, et al. Classical and molecular cytogenetic abnormalities and outcome of childhood acute myeloid leukaemia: report from a referral centre in Israel. Brit J Haematol 2004; 126: 320–37.
- 18 Kong XT, Ida K, Ichikawa H, et al. Consistent detection of TLS/FUS-ERG chimeric transcripts in acute myeloid leukemia with t(16;21)(p11;q22) and identification of a novel transcript. Blood 1997; 90: 1192–9.
- 19 Lam DH, Aplan PD. NUP98 gene fusions in hematologic malignancies. Leukemia 2001; 15: 1689–95.
- 20 Ma Z, Morris SW, Valentine V, et al. Fusion of two novel genes, RBM15 and MKL1, in the t(1;22)(p13;q13) of acute megakaryoblastic leukemia. Nature Genet 2001; 28: 220–1.
- 21 Shaffer LG, Tommerup N, eds. ISCN 2005. An International System for Cytogenetic Nomenclature. Basel: S Karger.
- 22 Therneau TM, Grambsch PM. Modeling Survival Data. New York: Springer, 2000.
- 23 Visani G, Bernasconi P, Boni M, et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leukemia–analysis of 848 patients. Leukemia 2001; 15: 903–9.
- 24 Wells RJ, Arthur DC, Srivastava A, et al. Prognostic variables in newly diagnosed children and adolescents with acute myeloid leukemia: Children’s Cancer Group Study 213. Leukemia 2002; 16: 601–7.
- 25 Hann IM, Webb DK, Gibson BE, Harrison CJ. MRC trials in childhood acute myeloid leukaemia. Ann Hematol 2004; 83: 108–12.
- 26 Kardos G, Baumann I, Passmore SJ, et al. Refractory anemia in childhood: a retrospective analysis of 67 patients with particular reference to monosomy 7. Blood 2003; 102: 1997–2003.
- 27 Sandoval C, Head DR, Mirro J Jr, Behm FG, Ayers GD, Raimondi SC. Translocation t(9;11)(p21;q23) in pediatric de novo and secondary acute myeloblastic leukemia. Leukemia 1992; 6: 513–9.
- 28 Mrozek K, Heinonen K, Lawrence D, et al. Adult patients with de novo acute myeloid leukemia and t(9;11)(p22;q23) have a superior outcome to patients with other translocations involving band 11q23: a cancer and leukemia group B study. Blood 1997; 90: 4532–8.
- 29
Kondo M,
Horibe K,
Takahashi Y,
Matsumoto K,
Fukuda M,
Inaba J,
Kato K,
Kojima S,
Matsuyama T.
Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia.
Med Pediatr Oncol
1999; 33: 525–9.
10.1002/(SICI)1096-911X(199912)33:6<525::AID-MPO1>3.0.CO;2-8 CAS PubMed Web of Science® Google Scholar
- 30 Bienz M, Ludwig M, Leibundgut EO, Mueller BU, Ratschiller D, Solenthaler M, Fey MF, Pabst T. Risk assessment in patients with acute myeloid leukemia and a normal karyotype. Clin Cancer Res 2005; 11: 1416–24.
- 31 Meshinchi S, Woods WG, Stirewalt DL, Sweetser DA, Buckley JD, Tjoa TK, Bernstein ID, Radich JP. Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia. Blood 2001; 97: 89–94.
- 32 Zwaan CM, Meshinchi S, Radich JP, et al. FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance. Blood 2003; 102: 2387–94.